Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
25.54
-1.46 (-5.41%)
Nov 6, 2026, 4:00 PM EST - Market closed
Arcutis Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 506.68 | 372.07 | 166.54 | 29.19 | 3.69 | - |
Other Revenue | 2 | 4 | 30 | 30.42 | - | - |
| 508.68 | 376.07 | 196.54 | 59.61 | 3.69 | - | |
Revenue Growth | 60.00% | 91.34% | 229.73% | 1517.09% | - | - |
Cost of Revenue | 44.87 | 36.7 | 19.13 | 4.99 | 0.75 | - |
Gross Profit | 463.81 | 339.38 | 177.41 | 54.62 | 2.93 | - |
Selling, General & Admin | 334.79 | 274.55 | 229.39 | 185.15 | 122.12 | 60.97 |
Research & Development | 93.86 | 77.05 | 76.42 | 110.58 | 182.44 | 145.56 |
Operating Expenses | 428.65 | 351.6 | 305.81 | 295.72 | 304.56 | 206.53 |
Operating Income | 35.16 | -12.23 | -128.4 | -241.1 | -301.63 | -206.53 |
Interest Expense | -13.73 | -12.08 | -27.17 | -29.71 | -15.65 | - |
Interest & Investment Income | 9.32 | 8.9 | 16.13 | 12.52 | 5.82 | 0.17 |
Other Non Operating Income (Expenses) | 0.06 | 0.44 | 0.05 | -0.73 | - | - |
Pretax Income | 30.8 | -14.97 | -139.39 | -259.03 | -311.46 | -206.36 |
Income Tax Expense | 0.89 | 1.17 | 0.65 | 3.11 | - | - |
Net Income | 29.91 | -16.14 | -140.04 | -262.14 | -311.46 | -206.36 |
Net Income to Common | 29.91 | -16.14 | -140.04 | -262.14 | -311.46 | -206.36 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 130 | 127 | 121 | 69 | 55 | 49 |
Shares Outstanding (Diluted) | 134 | 127 | 121 | 69 | 55 | 49 |
Shares Change | 6.17% | 5.19% | 74.53% | 25.94% | 11.39% | 38.52% |
EPS (Basic) | 0.23 | -0.13 | -1.16 | -3.78 | -5.66 | -4.18 |
EPS (Diluted) | 0.22 | -0.13 | -1.16 | -3.78 | -5.66 | -4.18 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 59.71 | -6.31 | -112.3 | -247.49 | -258.05 | -175.62 |
Free Cash Flow Per Share | 0.45 | -0.05 | -0.93 | -3.57 | -4.69 | -3.56 |
Gross Margin | 91.18% | 90.24% | 90.27% | 91.63% | 79.54% | - |
Operating Margin | 6.91% | -3.25% | -65.33% | -404.49% | -8183.04% | - |
Profit Margin | 5.88% | -4.29% | -71.25% | -439.79% | -8449.76% | - |
Free Cash Flow Margin | 11.74% | -1.68% | -57.14% | -415.20% | -7000.76% | - |
EBITDA | 37.41 | -7.56 | -126.44 | -240.35 | -300.69 | -206.08 |
EBITDA Margin | 7.36% | -2.01% | -64.33% | - | - | - |
D&A For EBITDA | 2.25 | 4.67 | 1.96 | 0.75 | 0.93 | 0.45 |
EBIT | 35.16 | -12.23 | -128.4 | -241.1 | -301.63 | -206.53 |
EBIT Margin | 6.91% | -3.25% | -65.33% | - | - | - |
Revenue as Reported | 508.68 | 376.07 | 196.54 | 59.61 | 3.69 | - |
Advertising Expenses | - | 25.3 | 6.9 | 11.2 | 1.5 | - |